Research coverage runs from preclinical mechanism papers to AI-driven peptide discovery. Most of what shows up here lives in Nature, Cell, Science, JAMA, and the abstracts from AACR, ESCMID, AAN, and ESCMID Global.
A few threads keep recurring. Macrocyclic and bicyclic peptides keep getting better at hitting "undruggable" targets — KRAS, beta-catenin, intracellular protein–protein interactions. Antimicrobial peptides have moved from theory to clinical candidates against carbapenem-resistant organisms and biofilms. Cancer peptide vaccines (ELI-002, autogene cevumeran, EVX-01) are producing real survival data. AI design tools — protein language models, transformer architectures, de novo platforms — are starting to generate hits that humans wouldn't.
If you want the lab side without the press releases, this is the right surface. The stories below name the lab, the journal, and the result.
Researchers at Anglia Ruskin University published a systematic review and meta-analysis in Cardiovascular Diabetology - Endocrinology Reports on May 20 covering long-term cardiovascular outcomes for glucagon-like peptide-1 receptor agonists in high-risk cardiovascular populations. The review aggregated data from more than 90,000 participants across large international clinical trials. The headline finding: GLP-1 receptor agonists significantly reduce the risk of heart attacks, strokes, heart failure, and premature death over the long term in patients with established cardiovascular disease and high cardiovascular risk. The review extends the SELECT 20% MACE-reduction signal to the broader high-risk-CV population and joins the established cardiovascular-outcomes evidence base alongside the LEADER (liraglutide), SUSTAIN-6 (semaglutide), and STEP-HFpEF (semaglutide in heart failure) trial readouts. The Anglia Ruskin synthesis is the broadest evidence aggregation to date — directly relevant to the Medicare GLP-1 Bridge that begins July 1, 2026.
A 2026 Nature Communications paper introduced AMPLiT — a tool for screening antimicrobial peptide candidates in metagenomic datasets — and applied it to human coprolite metagenomes (ancient stool samples). The team identified candidate AMPs from extinct gut-microbiome lineages that have functional activity against modern multidrug-resistant pathogens. The approach extends the AMP-discovery search space from contemporary microbial sequences to the much-larger reservoir of evolutionary AMPs encoded in ancient host-microbiome assemblies preserved in archaeological samples. The strategy joins the broader 2026 AI-AMP wave (ProteoGPT, CAMPER, the AI-driven AMP characterization paper in Scientific Reports) as an alternative source of novel chemistry against ESKAPE pathogens. The work positions ancient-DNA-based AMP discovery as a credible track alongside computational design.
A Nature Communications paper from a Texas A&M Health team published May 19 reported the engineering of genetically encoded calcium release-activated calcium channel (CRAC) inhibitory binders called CRABs — peptide inhibitors derived from the ORAI C-terminal tail that selectively interfere with STIM1-ORAI coupling. The plasma-membrane-anchored CRAB variant potently inhibits calcium influx and downstream NFAT signaling. The platform spans optogenetic (Opto-CRAB) and chemogenetic (Chemo-CRAB) variants for graded, real-time control of CRAC activity. In a zebrafish Stormorken syndrome model, CRABs rescued thrombocyte progenitor production. The therapeutic implication: a peptide-based adjustable brake on T-cell calcium signaling that could enable safer, more controllable immune cell therapies — CAR-T cytokine release moderation, autoimmune T-cell quenching, transplantation tolerance induction.
A Journal of Peptide Science paper reported a novel four-amino-acid peptide WDGL (Trp-Asp-Gly-Leu) derived from Ulva prolifera — the green algae species responsible for major coastal blooms in East Asia. The peptide was identified through virtual screening of marine-derived peptide libraries, binds Keap1 at key residues, and activates the Nrf2 antioxidant pathway in cellular oxidative-stress models. In vitro pharmacokinetic profiling showed favorable properties for further development. The mechanistic rationale: Keap1-Nrf2 activation drives expression of antioxidant response element (ARE)-regulated genes including superoxide dismutase, catalase, and glutathione peroxidase, reducing reactive oxygen species (ROS) and oxidative damage. The WDGL work joins a small but growing literature on tetrapeptides as drug-like scaffolds — Aivocode's CAQK brain-injury tetrapeptide being the other May 2026 example. Marine-derived AMP and bioactive peptide discovery remains an underexplored chemistry frontier.
A Science magazine feature published May 8 highlighted iRGD — a 9-amino-acid tumor-penetrating peptide originally identified by Erkki Ruoslahti's group at Sanford Burnham Prebys — as a candidate to improve delivery of cancer chemotherapy and immunotherapy into solid tumors. iRGD binds α-v integrins overexpressed on tumor vasculature, then is proteolytically processed to expose a cryptic CendR motif that engages neuropilin-1 and triggers a transient tumor-vascular permeability burst. Co-administered with chemotherapy, iRGD increases drug penetration into the tumor without covalent conjugation. Early clinical studies in pancreatic cancer combining iRGD with nab-paclitaxel and gemcitabine showed improved tumor response and progression-free survival; later-stage development continues through DrugCendR (the Ruoslahti lab spinout) and academic-industrial partnerships. The Science piece frames iRGD as a complementary technology to antibody-drug conjugates and peptide-drug conjugates — a co-administered delivery enhancer rather than a covalent payload carrier.
Fadi Shehadeh, Biswajit Mishra and collaborators published CAMPER (Constraint-driven AMP Engineering with Ranking) in Nature Communications 2026, integrating machine learning with mechanistic biological features to design peptides that target MRSA persister cells. The lead candidate, WP-CAMPER1, kills S. aureus MW2 at a minimal inhibitory concentration of 4 µg/mL. A 2% topical formulation reduced bacterial burden 2.5 log10 in a murine prophylactic skin infection model; the D-enantiomer WP-CAMPER1-d achieved 1.37 log10 reduction in established biofilm infections.
A Nature Communications paper details crystalline mesoporous frameworks built from amphiphilic collagen-mimetic peptides (aCMPs) — charge-segregated collagen-mimetic sequences modified with lipid tails at their N-termini. Hydrophobic and electrostatic interactions drive 3D porous architectures whose lattice packing tracks with lipid-tail length (C12, C10, C8); shortening to C6 flips assembly into nanosheets. The work expands peptide-based biomaterials beyond the triple helix and offers a programmable scaffold platform for drug delivery and tissue engineering.
A Cell Biomaterials review published April 16 maps the AI-driven antibiotic-discovery landscape across two strategy families: mining (using discriminative models on genomic/proteomic sequence libraries) and generation (using diffusion and language models to design novel synthetic peptides exceeding nature's repertoire). Companion work flagged in the review includes the University of Pennsylvania AMP-Diffusion system, which produced tens of thousands of candidate peptides — 46 prioritized, three quarters bacterial-inhibitory, and two with in vivo efficacy matching approved antibiotics in mouse infection models.
A Nature Chemical Biology paper published May 2026 reported TerminaTOR, a genetically encoded peptide inhibitor of mTORC1 that can be targeted to specific subcellular locations and used to dissect mTORC1 biology in living cells. Targeted to the lysosome, TerminaTOR inhibits canonical lysosomal mTORC1 and induces autophagy — recapitulating rapamycin's pharmacology. Targeted to the nucleus, TerminaTOR specifically inhibits nuclear mTORC1 and reveals a previously uncharacterized regulatory function: nuclear mTORC1 controls transcription of CCAAT-motif-containing genes and promotes cancer cell proliferation. The work creates a tool for spatially separating canonical (cytoplasmic) and noncanonical (nuclear) mTORC1 functions and identifies nuclear mTORC1 as a potentially druggable axis distinct from the lysosomal pathway. Therapeutic implication: cancer programs targeting mTORC1 might benefit from nucleus-selective inhibitors that spare lysosomal autophagy.
A Nature Communications paper published May 13, 2026 reported that chiral engineering of tripeptide-drug conjugates (PDCs) — systematically varying the L/D amino-acid configuration in the peptide moiety — controls phase behavior between liquid-liquid phase separation (LLPS) and β-sheet-rich hydrogel formation. PDCs with alternating L/D residues underwent LLPS in solution; all-L or all-D PDCs formed structured hydrogels. The chirality-controlled phase behavior is a design lever for PDC drug-product engineering: LLPS-prone conjugates dissolve readily for parenteral dosing, while hydrogel-forming variants enable sustained-release depots or injection-site retention. The work expands the design space for peptide-drug conjugate formulation, joining the broader May 2026 PDC research cycle alongside the Avacta AVA6103 FOCUS-01 trial start and the Bicycle Therapeutics ASCO Duravelo-2 readout.
Beijing Frontier Research Center for Biological Structure (FRCBS) at Tsinghua University organized an international Peptide Design Competition this year with about 300 participants from around the world designing peptide candidates targeting NK2R — a G-protein-coupled receptor involved in energy metabolism and appetite regulation. The competition is structured as a benchmarking exercise to test how well AI-driven structural predictions hold up under experimental scrutiny, with participants submitting designs that are then synthesized and tested for binding and functional activity. NK2R is a target of growing interest in the obesity-pharmacology field as the GLP-1 receptor space saturates and pharmaceutical R&D groups look for the next-generation metabolic-disease receptor that could complement GLP-1/GIP/glucagon agonism. The framework — AI design followed by wet-lab validation — is positioned as a community blueprint for de novo peptide discovery at large.
A 2026 Pharmaceuticals (MDPI) comment paper responds to the Józwiak et al. 2025 multifunctionality review of BPC-157, focusing on the peptide's role in targeting angiogenesis and modulating nitric oxide's cytotoxic versus protective actions. The response paper argues BPC-157's clinical claim breadth — wound healing, GI ulcer repair, tendon healing, neuroprotection — derives from a single biochemical hub: the peptide's interaction with vascular endothelial growth factor receptor 2 (VEGFR2) signaling and the NO/cGMP axis. The discussion lands as BPC-157 sits on the FDA's bulks-list review track for the July 23-24 PCAC meeting, with the underlying mechanistic literature still anchored on a small number of research groups. The Pharmaceuticals exchange illustrates the pre-clinical evidence gap that PCAC will weigh against the wide compounding-pharmacy demand signal.
A Molecular Therapy Oncology 2026 paper from a multi-institution collaboration reported that a peptide engineered against Fibulin-4 — a glycoprotein overexpressed in metastatic breast cancer extracellular matrix — successfully targeted and killed metastatic breast cancer cells in mice. The same peptide doubles as an imaging probe, supporting peptide-based detection alongside therapy. The Fibulin-4 target is significant because metastatic breast cancer remains the leading cause of breast cancer mortality and current targeted therapies (HER2, hormone-receptor) leave a substantial therapy gap for triple-negative metastatic disease. The work joins the broader peptide-drug-conjugate field in which six PDCs are in Phase 3 trials and roughly 96 are in development, even as only Lutathera holds active FDA approval after the 2024 Pepaxto withdrawal.
A Chemical Communications (Royal Society of Chemistry) 2026 review on peptide-based drug design using generative AI synthesizes the methods landscape behind the wave of community competitions and pharmaceutical-industry de novo programs that landed in 2026. The review covers ProteoGPT and related protein-language-model architectures, AlphaFold3-based pose prediction, diffusion-model peptide structure generation, and the experimental-validation cycle that turns AI designs into bench-tested candidates. It frames the Tsinghua FRCBS NK2R Peptide Design Competition and the published ultra-long-acting GLP-1 receptor agonist de novo design work as proof-points that the AI-design stack has crossed the threshold from generative novelty to drug-discovery utility. The piece lands as the AI/peptide field tracks toward routine kilogram-scale syntheses (enlicitide PCSK9, others) and into Phase 1/2 candidates inside roughly 18 months from in silico design.
A Nature Biotechnology paper from a multi-institution collaboration introduced deep peptide recognition profiling (PRP) — a yeast-display platform integrated with protein-language models that maps T-cell receptor binding across the proteome for individual TCRs. Applied to HLA-B*27:05-restricted TCRs from patients with ankylosing spondylitis and acute anterior uveitis, the platform identified hundreds to over 6,000 unique peptide ligands per TCR and surfaced candidate autoantigens. Predicted binding scores correlated significantly with experimental T-cell activation across multiple TCRs. The model outperformed AlphaFold3 and tFold-TCR in predicting T-cell activation — meaningful for autoimmune-disease antigen discovery and personalized neoantigen cancer-vaccine design alike. The mechanistic implication: the CDR3β loop arches over the center of the HLA-B27-bound peptide and accounts for most contacts, with CDR3α positioned peripherally.
A 2026 Discover Oncology review (Springer Nature) consolidated the case for antimicrobial peptides (AMPs) as anticancer therapeutics across three mechanistic categories: direct cytotoxicity through cancer-cell-membrane disruption (the same cationic-amphipathic chemistry that makes AMPs antibacterial works on the negatively charged outer leaflet of cancer-cell membranes), intracellular targeting of mitochondria and DNA replication, and use as vaccine adjuvants that boost immune responses to neoantigens. The review joins the May 2026 International Journal of Peptide Research piece on peptide cancer vaccines, the Frontiers in Medicine April 2026 anticancer AMP review, and the Frontiers in Bioinformatics March 2026 computational AMP discovery review as part of the AMP-as-cancer-therapeutic literature wave. Clinical translation remains limited: AMP-based cancer drugs in development are mostly preclinical or Phase 1.
April-May 2026 produced an unusual concentration of peer-reviewed advances against antimicrobial resistance, with peptide therapeutics anchoring much of the progress. The Frontiers in Bioinformatics March 17 review documented an AI/LLM pipeline (ProteoGPT) that produced 17 active peptides out of 18 designed (94.4% hit rate) in 48 days — collapsing the traditional discovery timeline. A Nature Microbiology generative-AI approach produced novel AMPs against multidrug-resistant bacteria with anti-inflammatory effects and minimal cytotoxic risk. Other April-May 2026 breakthroughs: Houston Methodist's CAMPER engineered against MRSA, the Manchester team's alternative ligase pathway to penicillins, and the Indian Institute of Technology Roorkee antibacterial peptide-drug conjugate against NDM-1/IMP-1 metallo-beta-lactamase pathogens. The combined wave signals the peptide-design stack has matured enough to compete directly with small-molecule antibiotic development.
A review article published in the International Journal of Peptide Research and Therapeutics in May 2026 consolidates the current state of peptide-based cancer vaccines, covering antigen selection, adjuvant chemistry, and delivery platforms designed to address tumor evolution and immune escape. The review argues that despite persistent challenges around peptide stability and limited immunogenicity, the combination of nanomaterials and adjuvants has significantly enhanced immune response efficiency and targeted delivery — with applications in drug-resistant and metastatic cancers. The piece sits alongside two other May peptide vaccine reviews (WIRES Nanomedicine, Science Advances) and frames the ASCO 2026 peptide-oncology slate (BioVaxys MVP-S, BriaCell Bria-IMT, Evaxion EVX-01) as the clinical pipeline backing the review-paper momentum.